Search research articles
Contact Us
Filters
Showing results (41-50 of 167) with videos related to
Page
of 17
Sort By:
Free Radical Biology & Medicine
|
February 19, 2013
The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies
Kristy Lee, Margaret M Briehl, Andrew P Mazar, et al.
Haematologica
|
February 21, 2009
CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression
Lisa M Rimsza, Wing C Chan, Randy D Gascoyne, et al.
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood
|
August 6, 2005
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Margaret E Tome, David B F Johnson, Lisa M Rimsza, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
British Journal of Haematology
|
October 16, 2024
CDK8/19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytes
Zhi-Jian Liu, Christopher Thom, Ioana I Nitulescu, et al.
Blood
|
December 15, 2011
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
Sarah T Wilkinson, Kristie A Vanpatten, Diane R Fernandez, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 24, 2007
Umbilical cord blood produces small megakaryocytes after transplantation
Mark Ignatz, Martha Sola-Visner, Lisa M Rimsza, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 167) with videos related to
Sort By:
Page
of 17
Free Radical Biology & Medicine
|
February 19, 2013
The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies
Kristy Lee, Margaret M Briehl, Andrew P Mazar, et al.
Haematologica
|
February 21, 2009
CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression
Lisa M Rimsza, Wing C Chan, Randy D Gascoyne, et al.
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood
|
August 6, 2005
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Margaret E Tome, David B F Johnson, Lisa M Rimsza, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2008
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
Daniel O Persky, Joseph M Unger, Catherine M Spier, et al.
British Journal of Haematology
|
October 16, 2024
CDK8/19 inhibition triggers a switch from mitosis to endomitosis in cord blood megakaryocytes
Zhi-Jian Liu, Christopher Thom, Ioana I Nitulescu, et al.
Blood
|
December 15, 2011
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
Sarah T Wilkinson, Kristie A Vanpatten, Diane R Fernandez, et al.
Haematologica
|
January 25, 2012
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O Persky, David Dornan, Bryan H Goldman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 24, 2007
Umbilical cord blood produces small megakaryocytes after transplantation
Mark Ignatz, Martha Sola-Visner, Lisa M Rimsza, et al.
Page
of 17